keyword
MENU ▼
Read by QxMD icon Read
search

Ranibizumab

keyword
https://www.readbyqxmd.com/read/28527480/safety-and-effectiveness-of-cataract-surgery-with-simultaneous-intravitreal-anti-vegf-in-patients-with-previously-treated-exudative-age-related-macular-degeneration
#1
Manuel Sousa Falcão, Paulo Freitas-Costa, João Nuno Beato, João Pinheiro-Costa, Amândio Rocha-Sousa, Ângela Carneiro, Elisete Maria Brandão, Fernando Falcão-Reis
INTRODUCTION: To evaluate the safety and impact on visual acuity, retinal and choroidal morphology of simultaneous cataract surgery and intravitreal anti-vascular endothelial growth factor on patients with visually significant cataracts and previously treated exudative age-related macular degeneration. MATERIAL AND METHODS: Prospective study, which included 21 eyes of 20 patients with exudative age-related macular degeneration submitted to simultaneous phacoemulsification and intravitreal ranibizumab or bevacizumab...
February 27, 2017: Acta Médica Portuguesa
https://www.readbyqxmd.com/read/28520642/inflammatory-choroidal-neovascular-membrane-long-term-visual-and-anatomical-outcomes-after-intravitreal-anti-vascular-endothelial-growth-factor-therapy
#2
Palmeera Dʼsouza, Ratnesh Ranjan, Upendra Babu, Anuradha V Kanakath, Veerappan R Saravanan
PURPOSE: To assess the long-term visual and anatomical outcomes after intravitreal anti-vascular endothelial growth factor therapy for inflammatory choroidal neovascular membrane (CNVM). METHODS: Retrospective case series of 15 consecutive cases of newly diagnosed inflammatory CNVM who were treated with intravitreal bevacizumab or ranibizumab injections. RESULTS: The study included 8 women and 7 men with mean age at presentation with CNVM of 40...
May 16, 2017: Retina
https://www.readbyqxmd.com/read/28520639/wrinkled-vascularized-retinal-pigment-epithelium-detachment-prognosis-after-intravitreal-anti-vegf-therapy
#3
Delphine Lam, Oudy Semoun, Rocio Blanco-Garavito, Camille Jung, Diem T Nguyen, Eric H Souied, Gerard Mimoun
BACKGROUND/PURPOSE: Neovascular age-related macular degeneration (nAMD) is frequently associated with vascularized pigment epithelial detachment (v-PED). We observed a peculiar characteristic of v-PED characterized by small lacy folds of the retinal pigment epithelium, appearing as a wrinkled PED (w-PED) on spectral domain optical coherence tomography (SD-OCT). Our purpose was to describe the visual prognosis and number of intravitreal injections in w-PED compared with non-w-PED. METHODS: In this retrospective, case-control series, we reviewed retrospectively medical records of 52 eyes of 51 patients who were consecutively included between November 1 and 30, 2015 with a previous minimum 3-year follow-up...
May 16, 2017: Retina
https://www.readbyqxmd.com/read/28520638/effects-of-intravitreal-ranibizumab-and-bevacizumab-on-the-retinal-vessel-size-in-diabetic-macular-edema
#4
Muhammed Mustafa Kurt, Osman Çekiç, Çetin Akpolat, Mustafa Elçioglu
PURPOSE: The goal of this study was to assess the effects of a single injection of intravitreal ranibizumab (RAN) or bevacizumab (BEV) on the retinal vessel size in eyes with diabetic macular edema. MATERIALS AND METHODS: In total, 32 patients were enrolled in the RAN group, and 30 patients were included in BEV group. Each of these groups was also subdivided into two others groups: a study group and a control group. The study groups were composed of the injected eyes, whereas the noninjected fellow eyes served as the control groups...
May 16, 2017: Retina
https://www.readbyqxmd.com/read/28513493/inflammatory-choroidal-neovascularization-in-indian-eyes-etiology-clinical-features-and-outcomes-to-anti-vascular-endothelial-growth-factor
#5
Rupak Roy, Kumar Saurabh, Aditya Bansal, Amitabh Kumar, Anindya Kishore Majumdar, Swakshyar Saumya Paul
BACKGROUND AND OBJECTIVES: The aim was to study the clinical profile of inflammatory choroidal neovascularization (CNV) and its treatment response to intravitreal bevacizumab or ranibizumab on pro re nata (PRN) basis in Indian eyes. MATERIALS AND METHODS: This was a retrospective case series of consecutive patients with inflammatory CNV treated with anti-vascular endothelial growth factor (anti-VEGF) in a tertiary eye care center in Eastern India between 2009 and 2014...
April 2017: Indian Journal of Ophthalmology
https://www.readbyqxmd.com/read/28512425/long-term-follow-up-of-polypoidal-choroidal-vasculopathy-secondary-to-angioid-streaks-treated-by-intravitreal-aflibercept-and-ranibizumab
#6
James G Wong, Katherine Yu Qian
PURPOSE: Angioid streaks (AS) are dehiscences in Bruch's membrane that may be idiopathic or associated with numerous systemic illnesses. Polypoidal choroidal vasculopathy (PCV) is an underdiagnosed exudative chorioretinopathy often characterised by serosanguineous detachments of the pigmented epithelium. The use of the anti-VEGF agents ranibizumab and aflibercept in the management of PCV secondary to AS has not been previously documented. We report 3 patients with active PCV secondary to AS, 1 of which had a family history of PCV secondary to AS, not previously reported in the literature...
January 2017: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/28508241/resource-use-and-real-world-outcomes-for-ranibizumab-treat-and-extend-for-neovascular-age-related-macular-degeneration-in-the-uk-interim-results-from-terra
#7
Yit Yang, Louise Downey, Hemal Mehta, Bushra Mushtaq, Niro Narendran, Nishal Patel, Praveen J Patel, Filis Ayan, Kara Gibson, Franklin Igwe, Pete Jeffery
INTRODUCTION: Ranibizumab is an inhibitor of vascular endothelial growth factor-A (anti-VEGF) approved for the treatment of neovascular age-related macular degeneration (nAMD). The treat and extend (T&E) regimen can potentially reduce the burden of clinic visits compared with a pro re nata (PRN) regimen. Retrospective, interim analyses of clinical effectiveness, treatment and resource use patterns were conducted using real-world data in England and Wales from the TERRA study. METHODS: Two cohorts, those switching from a PRN to a T&E regimen ('prior PRN') and those initiating ranibizumab on the T&E regimen as their first anti-VEGF therapy ('anti-VEGF-naïve') were enrolled in TERRA...
May 15, 2017: Ophthalmology and Therapy
https://www.readbyqxmd.com/read/28499055/sequential-sterile-intraocular-inflammation-associated-with-consecutive-intravitreal-injections-of-aflibercept-and-ranibizumab
#8
Dilraj S Grewal, Tayler Schwartz, Sharon Fekrat
The authors report the unique response of two patients treated for cystoid macular edema (CME) secondary to central retinal vein occlusion (CRVO) who developed sequential episodes of likely sterile inflammatory responses following separate intravitreal injections of aflibercept (Eylea; Regeneron, Tarrytown, NY) and ranibizumab (Lucentis; Genentech, South San Francisco, CA) despite multiple previous uneventful injections for CME secondary to CRVO. Following the twenty-fifth aflibercept and seventh ranibizumab injection, two patients developed an acute inflammatory response, which was treated empirically with intravitreal antibiotics and topical and oral steroids (in Case 2)...
May 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28498374/ranibizumab-pretreatment-in-diabetic-vitrectomy-a-pilot-randomised-controlled-trial-the-radivit-study
#9
O Comyn, L Wickham, D G Charteris, P M Sullivan, E Ezra, Z Gregor, G W Aylward, L da Cruz, D Fabinyi, T Peto, M Restori, W Xing, C Bunce, P G Hykin, J W Bainbridge
PurposeOur aim was to evaluate the impact of intravitreal ranibizumab pretreatment on the outcome of vitrectomy surgery for advanced proliferative diabetic retinopathy. The objective was to determine the feasibility of a subsequent definitive trial and estimate the effect size and variability of the outcome measure.Patients and methodsWe performed a pilot randomised double-masked single-centre clinical trial in 30 participants with tractional retinal detachment associated with proliferative diabetic retinopathy...
May 12, 2017: Eye
https://www.readbyqxmd.com/read/28496301/short-term-outcomes-in-patients-with-branch-retinal-vein-occlusion-who-received-intravitreal-aflibercept-with-or-without-intravitreal-ranibizumab
#10
Yoshihito Sakanishi, Ayumi Usui-Ouchi, Kazunori Tamaki, Keitaro Mashimo, Rei Ito, Nobuyuki Ebihara
PURPOSE: The purpose of this study was to determine the short-term outcomes for patients who received intravitreal aflibercept (IVA) with or without intravitreal ranibizumab (IVR) for macular edema (ME) due to branch retinal vein occlusion (BRVO). PATIENTS AND METHODS: Patients received IVA for ME due to BRVO. Patients who initially received IVA were defined as the treatment-naïve group and those who were switched from IVR to IVA after ME recurrence were defined as the switching group...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28496299/response-of-eyes-with-age-related-macular-degeneration-to-anti-vegf-drugs-and-implications-for-therapy-planning
#11
Noriko Miyamoto, Michiko Mandai, Hiroshi Kojima, Takanori Kameda, Masataka Shimozono, Akihiro Nishida, Yasuo Kurimoto
PURPOSE: To evaluate the response to and dependence on aflibercept or ranibizumab in patients with age-related macular degeneration (AMD). METHODS: We retrospectively reviewed AMD patients who received induction therapy with aflibercept or ranibizumab for the following parameters: whether complete resolution of the retinal fluid ("good response") was achieved and whether recurrence was observed within 3 months ("dependent") after the induction treatment. With aflibercept treatment, treatment-naïve eyes with a good response/non-dependence were recommended a pro re nata regimen, and other eyes were recommended a proactive bimonthly regimen, followed by monitoring of visual acuity (VA) for 12 months...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28494491/topical-delivery-of-anti-vegf-drugs-to-the-ocular-posterior-segment-using-cell-penetrating-peptides
#12
Felicity de Cogan, Lisa J Hill, Aisling Lynch, Peter J Morgan-Warren, Judith Lechner, Matthew R Berwick, Anna F A Peacock, Mei Chen, Robert A H Scott, Heping Xu, Ann Logan
Purpose: To evaluate the efficacy of anti-VEGF agents for treating choroidal neovascularization (CNV) when delivered topically using novel cell-penetrating peptides (CPPs) compared with delivery by intravitreal (ivit) injection. Methods: CPP toxicity was investigated in cell cultures. Ivit concentrations of ranibizumab and bevacizumab after topical administration were measured using ELISA. The biological efficacy of topical anti-VEGF + CPP complexes was compared with ivit anti-VEGF injections using an established model of CNV...
May 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/28493086/ranibizumab-for-choroidal-neovascularization-secondary-to-pseudoxanthoma-elasticum-4-year-results-from-the-pixel-study-in-france
#13
Gérard Mimoun, Jean-Marc Ebran, Typhaine Grenet, Alain Donati, Salomon-Yves Cohen, Anne Ponthieux
PURPOSE: To evaluate the long-term effectiveness and safety of ranibizumab 0.5 mg in patients with choroidal neovascularization (CNV) secondary to pseudoxanthoma elasticum (PXE) in a real-world setting. METHODS: A descriptive, observational, multicenter study in a retrospective and prospective cohort was conducted in France that included patients who had received at least one injection of ranibizumab 0.5 mg during the period October 2011 to October 2014, for CNV secondary to PXE...
May 10, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28492921/interim-safety-data-comparing-ranibizumab-with-panretinal-photocoagulation-among-participants-with-proliferative-diabetic-retinopathy
#14
Jeffrey G Gross, Adam R Glassman, Margaret J Klein, Lee M Jampol, Frederick L Ferris, Neil M Bressler, Roy W Beck
No abstract text is available yet for this article.
May 8, 2017: JAMA Ophthalmology
https://www.readbyqxmd.com/read/28492920/cost-effectiveness-of-intravitreous-ranibizumab-compared-with-panretinal-photocoagulation-for-proliferative-diabetic-retinopathy-secondary-analysis-from-a-diabetic-retinopathy-clinical-research-network-randomized-clinical-trial
#15
David W Hutton, Joshua D Stein, Neil M Bressler, Lee M Jampol, David Browning, Adam R Glassman
Importance: The Diabetic Retinopathy Clinical Research Network Protocol S randomized clinical trial results suggest that ranibizumab is a reasonable treatment alternative to panretinal photocoagulation (PRP) when managing proliferative diabetic retinopathy (PDR), with or without concomitant baseline diabetic macular edema (DME). However, ranibizumab injections are costly. Thus, it would be useful to examine the relative cost-effectiveness of these 2 treatment modalities. Objective: To evaluate incremental cost-effectiveness ratios of 0...
May 8, 2017: JAMA Ophthalmology
https://www.readbyqxmd.com/read/28492435/clinical-findings-of-eyes-with-macular-edema-associated-with-branch-retinal-vein-occlusion-refractory-to-ranibizumab
#16
Taiji Hasegawa, Taizo Kawano, Ichiro Maruko, Hideki Koizumi, Tomohiro Iida
PURPOSE: To determine the relationship between the clinical findings and the response to ranibizumab therapy in eyes with macular edema associated with branch retinal vein occlusion. METHODS: We reviewed the medical records of 68 patients with macular edema associated with a branch retinal vein occlusion. The patients were placed in the refractory group if the central foveal thickness remained more than 250 μm throughout the 6-month study period despite the ranibizumab therapy; otherwise, they were placed in the responsive group...
May 10, 2017: Retina
https://www.readbyqxmd.com/read/28491468/recurrence-of-retinopathy-of-prematurity-in-zone-ii-stage-3-after-ranibizumab-treatment-a-retrospective-study
#17
Qinrui Hu, Yujing Bai, Xiaoli Chen, Lvzhen Huang, Yi Chen, Xiaoxin Li
Objective. To determine the prevalence and risk factors for the recurrence of retinopathy of prematurity (ROP) in Zone II Stage 3+ after ranibizumab treatment. Methods. This was a retrospective, nonrandomized, noncontrolled study that excluded Zone I and aggressive posterior ROP (APROP) cases. Infants who developed Zone II Stage 3 ROP with plus disease and underwent initial intravitreal injection of ranibizumab (IVR) were recruited. Patients were divided into 2 groups based on the outcome after initial ranibizumab treatment: recurrence of ROP or favorable outcome...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/28489694/efficacy-of-intravitreal-ranibizumab-injections-in-the-treatment-of-vitreous-hemorrhage-related-to-proliferative-diabetic-retinopathy
#18
Elias Chelala, Joseph Nehme, Hala El Rami, Roni Aoun, Ali Dirani, Ali Fadlallah, Alex Jalkh
PURPOSE: To investigate the efficacy of intravitreal ranibizumab injections in proliferative diabetic retinopathy associated with vitreous hemorrhage (VH). METHODS: A prospective study including patients with proliferative diabetic retinopathy who presented with persistent VH. Vitreous hemorrhage was graded into mild, moderate, and severe. Patients were randomized into two groups: the ranibizumab group was treated with intravitreal injections of ranibizumab and the control group was assigned to observation alone...
May 9, 2017: Retina
https://www.readbyqxmd.com/read/28484955/ranibizumab-in-the-treatment-of-diabetic-macular-edema-a-review-of-the-current-status-unmet-needs-and-emerging-challenges
#19
REVIEW
Nikolaos Dervenis, Athanasia Maria Mikropoulou, Paris Tranos, Panagiotis Dervenis
Diabetic retinopathy (more specifically diabetic macular edema, DME) is the most common cause of loss of vision in the working population in developed countries. Anti-vascular endothelial growth factor (anti-VEGF) agents considerably changed the treatment algorithms and improved prognosis of center-involving DME. Ranibizumab was the first approved anti-VEGF agent that revolutionized DME treatment. The vast increase in the number of patients undergoing intravitreal treatment and the role of anti-VEGF pharmacotherapy as the mainstay of DME treatment have triggered several challenges...
May 8, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28475181/a-systematic-review-to-assess-the-treat-and-extend-dosing-regimen-for-neovascular-age-related-macular-degeneration-using-ranibizumab
#20
REVIEW
S R Rufai, H Almuhtaseb, R M Paul, B L Stuart, T Kendrick, H Lee, A J Lotery
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the developed world. Monthly or as-needed (PRN) dosing strategies of intravitreal ranibizumab have been established as efficacious treatment options for neovascular AMD. More recently, the 'treat-and-extend' dosing regimen (TREX) is being adopted in clinical practice as it represents a patient-centric and economical option, reducing treatment burden by extending injection intervals when possible. However, the efficacy of TREX using ranibizumab monotherapy remains to be defined...
May 5, 2017: Eye
keyword
keyword
1767
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"